Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of serum thymic factors to preparation of anti-tumor medicine and protection medicine of tumor physical and chemical treatment medicine

A technology of serum thymus factor and medicine, applied in the field of application of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs

Inactive Publication Date: 2012-09-26
中国生化制药工业协会
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there are no patents and research reports on the application of FTS as an anti-tumor and immune-enhancing drug at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of serum thymic factors to preparation of anti-tumor medicine and protection medicine of tumor physical and chemical treatment medicine
  • Application of serum thymic factors to preparation of anti-tumor medicine and protection medicine of tumor physical and chemical treatment medicine
  • Application of serum thymic factors to preparation of anti-tumor medicine and protection medicine of tumor physical and chemical treatment medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] This embodiment relates to the results of the EAC ascites tumor group

[0056] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model mice were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the doses were 0.25 mg·kg -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; the positive drug group, 5-fluorouracil, once every other day, three times in total. The results are shown in Table 1:

[0057] Table 1 The results of FTS for anti-EAC ascites tumor drugs (χ±s, n=10)

[0058] group

Survival time (days)

life extension rate

high dose

medium dose

low dose

positive control

blank control

18.3±3...

Embodiment 2

[0062] This example relates to the results of the H22 solid tumor group

[0063] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model mice were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the doses were 0.25 mg·kg -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide administered once. The results are shown in Table 2.

[0064] Table 2 FTS is used for the result of anti-H22 solid tumor drug ( n=10)

[0065] group

Weight of solid tumor (g)

Tumor inhibition rate

high dose

medium dose

low dose

positive control

blank control

2.5±0.9 ΔΔ

2.7±0.7 ΔΔ

3.1±1.4

0.6±0....

Embodiment 3

[0069] This embodiment relates to the results of the Walker-256 tumor group

[0070] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model rats were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the dose was 2.2 mg·kg -1 , medium dose 1.1mg·kg -1 , low dose 0.55mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide administered once. The results are shown in Table 3.

[0071] The next day after the last administration in the treatment group, the solid tumors were dissected out and weighed, and the tumor inhibition rate was calculated. The tumor inhibition rates of the administration groups were all greater than 30%, and there was a quantitative-effect relationship, and the cura...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of serum thymic factors (FTS) to the preparation of anti-tumor medicine and protection medicine of tumor physical and chemical treatment medicine or immunity enhancing medicine. Experimental results show that each medication group of bearing cancer small mice and W256 big mice and a physiological saline group have obvious difference, and in addition, the tumor inhibition rates are all higher than 30 percent, so the FTS anti-tumor effect is exact. The FTS can also improve the immunity activity of the organism in various aspects, and can enhance the organism immunity function. The FTS is innoxious, the generated side effect is very little, in addition, the effective acting dosage range of the FTS is wide, and the safety range is large. The effect that theFTS has the obvious protection effect on the organism immunity indexes is discovered in the research of using the FTS as the protection medicine of the tumor physical and chemical treatment medicine.Thereby, the FTS can provide a novel target and development direction for tumor treatment on clinics.

Description

[0001] This application is a divisional application of Chinese patent application 200710002734.3. [0002] Original application date: 2007-1-25 [0003] Original application number: 200710002734.3 [0004] Invention name of the original application: Use of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs technical field [0005] The invention relates to a new application of biochemical substances in pharmaceutical engineering, more specifically the application of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs or immune-enhancing drugs. Background technique [0006] Cancer is one of the main causes of human death. According to the statistics of the World Health Organization, there are about 5 million patients who die of cancer every year in the world. In recent years, due to the deterioration of our living environment, the inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/08A61P35/00
Inventor 徐康森乐嘉静廖晓泉王悦张长平李湛君
Owner 中国生化制药工业协会
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com